Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
Langford
N J
NJ
Clinical Pharmacology Section, Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, UK. n.j.langford@bham.ac.uk
Kendall
M J
MJ
D001682:Biological Availability; D018678:Cholinergic Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D015248:Gemfibrozil / Q000009:adverse effects / Q000493:pharmacokinetics; D006331:Heart Diseases / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000503:physiopathology; D012307:Risk Factors
D018678:Cholinergic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D003577:Cytochrome P-450 Enzyme System; D015248:Gemfibrozil